1. Insanitary conditions at compounding facilities Publication: Silver Spring, MD : Center for Drug Evaluation and Research, November 2020 Subject(s): Drug CompoundingDrug Industry -- standardsFacility Regulation and ControlUnited StatesUnited States. Department of Health and Human ServicesUnited States. Food and Drug Administration
2. Enforcement policy for the Quality Standards of the Mammography Quality Standards Act during the COVID-19 public health emergency: guidance for mammography facilities, state MQSA contract partners, FDA approved MQSA accreditation bodies, and Food and Drug Administration staff Publication: [Silver Spring, MD] : Center for Devices and Radiological Health, December 2020 Subject(s): Facility Regulation and ControlMammography -- standardsCOVID-19United StatesUnited States. Department of Health and Human ServicesUnited States. Food and Drug Administration
3. Review timelines for applicant responses to complete response letters when a facility assessment is needed during the COVID-19 public health emergency Publication: [Silver Spring, MD] : Center for Drug Evaluation and Research, December 2020 Subject(s): Correspondence as TopicDrug ApprovalDrug IndustryFacility Regulation and ControlCOVID-19United StatesUnited States. Department of Health and Human ServicesUnited States. Food and Drug Administration
4. Appeal options available to mammography facilities concerning adverse accreditation decisions, suspension/revocation of certificates, or patient and physician notification orders: guidance for mammography facilities and Food and Drug Administration staff Publication: [Silver Spring, MD] : Center for Devices and Radiological Health, March 2, 2022 Subject(s): AccreditationFacility Regulation and ControlMammographyUnited StatesUnited States. Department of Health and Human ServicesUnited States. Food and Drug Administration
